Lyon, France, January 29, 2019 – POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-
alcoholic steatohepatitis (NASH), today announced its schedule for the publication of financial information for 2019.
|
Event |
Date* |
|
2018 Fourth Quarter Financial Update |
February 12, 2019 |
|
2018 Full Year Statement |
March 21, 2019 |
|
2019 First Quarter Financial Update |
April 8, 2019 |
|
2019 Second Quarter Financial Update |
July 15, 2019 |
|
2019 First Half Statement |
August 26, 2019 |
|
2019 Third Quarter Financial Update |
October 7, 2019 |
|
2019 Fourth Quarter Financial Update |
February 12, 2020 |
*Subject to modification
All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company's website in the Investors' section.
About Poxel SA
Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We have successfully completed the Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S., Europe and Japan. Together, with our partner Sumitomo Dainippon Pharma, we are conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Our partner Roivant Sciences is responsible for Imeglimin’s development and commercialization in countries outside of Poxel’s partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first in class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is advancing into a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs, including deuterated drug candidates for metabolic, specialty and rare diseases. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxelpharma.com)
Contacts
Poxel SA
Jonae R. Barnes
Senior Vice President, Investor Relations and Public Relations
jonae.barnes@poxelpharma.com
+1 617 818 2985
Investor relations / Media - EU/US
Trophic Communications
Gretchen Schweitzer or Stephanie May
may@trophic.eu
+49 89 238 877 34 or +49 171 185 56 82
Investor relations / Media - France
NewCap
Alexia Faure/Nicolas Merigeau
poxel@newcap.eu
+33 1 44 71 94 94
Released January 29, 2019